BiomX Announces Discontinuation Of Ongoing Phase 2b Clinical Trial Of Nebulized Phage Therapy BX004 In Patients With CF Associated With Chronic Pseudomonas Aeruginosa Infections

Following internal analysis and Data Monitoring Committee (DMC) feedback, the Company has elected to discontinue the BX004 Cystic Fibrosis (CF) Phase 2b trial

 BiomX continues to see potential in BX011, its phage program for Staphylococcus aureus (S. aureus) infections associated with diabetic foot infections (DFI). The Company is also implementing cost cutting measures, while evaluating strategic alternatives

NESS ZIONA, Israel, Dec. 08, 2025 (GLOBE NEWSWIRE) --  BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced its discontinuation of the ongoing Phase 2b clinical trial of nebulized phage therapy BX004 in patients with CF associated with chronic Pseudomonas aeruginosa infections.

The decision to discontinue the CF Phase 2b trial follows the Company's previously announced safety review by the independent DMC on November 25, 2025. After assessing the DMC's recommendations and conducting an internal analysis of unexpectedly high rates of adverse events, the Company has elected to discontinue the trial. Additionally, the Company plans to implement cost-cutting measures including a significant reduction in workforce while reviewing other strategic alternatives, aimed at maximizing shareholder value.